Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 145,369 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorder Clear all
Completed Phase 2 Interventional

Yoga to Reduce Cancer Fatigue

NCT00583739
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Yoga
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Nov 7, 2026, 2:34 PM EST
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

NCT02807675
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, LIP, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Nov 7, 2026, 2:34 PM EST
Recruiting No phase listed Observational

Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)

NCT06968975
View directory record Official record
Conditions
Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Swiftwater, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 7, 2026, 2:34 PM EST
Completed Phase 2 Interventional Results available

A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer

NCT00192075
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Gemcitabine, avastin, 5FU/folinic acid, oxaliplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
15
States / cities
Tucson, Arizona • Beverly Hills, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Nov 7, 2026, 2:34 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

NCT06749457
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
AZD7760, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
40
States / cities
Huntsville, Alabama • Chula Vista, California • Glendale, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 2:34 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery

NCT07155057
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Nov 7, 2026, 2:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Fruit and Vegetable Prescription Program

NCT04072757
View directory record Official record
Conditions
Obesity
Interventions
Intervention Group, Control Group
Behavioral
Lead sponsor
BETH COMERFORD
Other
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Nov 7, 2026, 2:34 PM EST
Completed Phase 3 Interventional Results available

Pamidronate to Treat Osteogenesis Imperfecta in Children

NCT00005901
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Pamidronate (Aredia)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Up to 16 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Nov 7, 2026, 2:34 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Hypothyroidism Treated With Calcitonin

NCT03342001
View directory record Official record
Conditions
Hypothyroidism
Interventions
Calcitonin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Nov 7, 2026, 2:34 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis

NCT07916181
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis, Adult
Interventions
Intravenous fosmanogepix
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 2:34 PM EST
Recruiting Phase 3 Interventional

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 7, 2026, 2:34 PM EST
Completed Not applicable Interventional

Heart Failure Management Program Versus Usual Care

NCT01822912
View directory record Official record
Conditions
Cardiac Failure, Congestive Heart Failure
Interventions
Heart Failure Disease Management Program, Heart Failure Usual Care
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Not listed
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Nov 7, 2026, 2:34 PM EST
Completed Phase 2 Interventional Results available

Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary

NCT00066781
View directory record Official record
Conditions
Carcinoma of Unknown Primary
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
4
States / cities
Mason City, Iowa • Rochester, Minnesota • Lincoln, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Nov 7, 2026, 2:34 PM EST
Terminated Phase 1 Interventional

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

NCT03114319
View directory record Official record
Conditions
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma
Interventions
TNO155, TNO155 in combination with EGF816 (nazartinib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 7, 2026, 2:34 PM EST
Completed Phase 2 Interventional

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

NCT00338130
View directory record Official record
Conditions
Melanoma
Interventions
AZD6244, Temozolomide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Santa Monica, California • Aurora, Colorado • Miami Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Nov 7, 2026, 2:34 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Novel Mechanisms and Approaches to Treat Neonatal Sepsis

NCT02554630
View directory record Official record
Conditions
Complication of Prematurity, Immunologic Deficiency Syndromes
Interventions
Adjuvant, Blood Collection
Other
Lead sponsor
University of Florida
Other
Eligibility
Up to 55 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Nov 7, 2026, 2:34 PM EST
Recruiting Phase 4 Interventional

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

NCT06110130
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Empagliflozin 10 MG, Placebo
Drug
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
19 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 7, 2026, 2:34 PM EST
Completed Phase 3 Interventional

Prevention of Contrast Renal Injury With Different Hydration Strategies

NCT01218828
View directory record Official record
Conditions
Contrast Medium-induced Nephropathy
Interventions
LVEDP -Based hydration strategy, Standard hydration
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Nov 7, 2026, 2:34 PM EST
Terminated Phase 1 Interventional

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

NCT03876028
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel, Ibrutinib
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Nov 7, 2026, 2:34 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Dynamic Measures of Neurochemistry in Mood Disorders

NCT00178828
View directory record Official record
Conditions
Depression
Interventions
sertraline, bupropion
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Nov 7, 2026, 2:34 PM EST
Completed Phase 4 Interventional Results available

Combined Letrozole and Clomid in Women With Infertility and PCOS

NCT02802865
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility
Interventions
Clomiphene, Letrozole
Drug
Lead sponsor
Rachel Mejia
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Nov 7, 2026, 2:34 PM EST
Approved For Marketing No phase listed Expanded access

An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

NCT04256265
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
2 Months and older
U.S. locations
29
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Nov 7, 2026, 2:34 PM EST
Completed Phase 1Phase 2 Interventional Results available

Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction

NCT00547365
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Human immune globulin intravenous (IGIV)
Biological
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Knoxville, Tennessee • Powell, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Nov 7, 2026, 2:34 PM EST
Recruiting Not applicable Interventional

Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration

NCT07544667
View directory record Official record
Conditions
Pelvic Organ Prolapse (POP), Cystocele, Pelvic Floor Disorder
Interventions
Poly-L-Lactic Acid (Sculptra) injection, Placebo injection (sterile water)
Device · Other
Lead sponsor
Cassandra Kisby
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 7, 2026, 2:34 PM EST